T

Tolmar

www.tolmar.com link_icon

Market Research Report: Tolmar, Inc.



Company Overview



  • Name: Tolmar, Inc.

  • Mission: Dedicated to improving experiences and outcomes for patients and healthcare providers through innovative long-acting injectable treatments in urology, oncology, and endocrinology.

  • Founded: 2007, with roots tracing back to Atrix Labs founded in 1986.

  • Key People:

  • Anil D’Souza, Chief Executive Officer

  • Shawn Silvestri, President and Chief Operating Officer

  • Anjan Chatterjee, Chief Medical Officer

  • Michael Elm, Chief Legal Officer

  • Jeff Lederman, Chief Financial Officer

  • Steve Griffin, President, North America

  • Kevin Economos, SVP, Operations

  • Fernando German, President, Tolmar International

  • Headquarters:

  • Fort Collins, CO (Research & Manufacturing)

  • Buffalo Grove, IL (North America Commercial Operations)

  • Dublin, Ireland (Global Commercial Alliances and Strategic Sourcing)

  • Number of Employees: 1100+

  • Revenue: No information is available.

  • Known For: Specializing in developing, manufacturing, and marketing long-acting injectable pharmaceutical products, particularly in the fields of urology, oncology, and endocrinology.


Products



FENSOLVI®


  • Description: Subcutaneous injection for Central Precocious Puberty (CPP) treatment for children.

  • Features:

  • 6-month dosing schedule.

  • Designed to minimize doctor visits.

  • Used for patients older than 2 years, up to 8 years for boys and 9 years for girls.


ELIGARD®


  • Description: Injectable suspension for advanced prostate cancer therapy.

  • Features:

  • Androgen hormone suppression.

  • Flexible dosing schedule—1, 3, 4, or 6 months depending on patient needs.


JATENZO®


  • Description: Oral softgel for testosterone replacement therapy in men with low testosterone.

  • Features:

  • FDA-approved.

  • Twice-daily oral dosage.

  • Adjustable dosage to suit patient requirements.


Recent Developments



  • New Partnerships:

  • Collaboration with UpScriptHealth for direct-to-patient telemedicine access to oral testosterone therapy (October 2024).

  • Exclusive promotional agreement with pharma& Group for Rubraca® in the U.S. for prostate cancer treatment (October 2024).

  • Global license and development agreement with DelSiTech (October 2024).

  • Product Acquisitions:

  • Acquisition of JATENZO® for testosterone replacement therapy expanding its urology portfolio (October 2022).

  • Regulatory Approvals:

  • FENSOLVI received permanent J-Code from CMS, enhancing insurance claim processing (May 2021).

  • Market Expansions:

  • Establishing Tolmar Canada for ELIGARD® distribution (October 2021).

  • Product Innovation:

  • Transition of FENSOLVI® and ELIGARD® from dual to single syringe systems for improved patient experience.


Conclusion



Tolmar, Inc. continues to position itself as a leader in long-acting injectable pharmaceuticals with strategic worldwide operations and collaborations. It remains committed to addressing significant healthcare needs in oncology, urology, and endocrinology while ensuring strong partnerships and competitive offerings in testosterone replacement therapies.